Graham G. Walmsley's Form 4 filing
Akero Therapeutics, Inc.AKRO · filed Mar 27, 2025
- Accession no.
- 0000950170-25-046271
- Filed
- Mar 27, 2025
- Trade date
- Mar 25-27, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $8.79M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Graham G. WalmsleyCIK 0001777517 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 25, 2025 | Common Stock | PPurchaseAcquired | +91,309 | $44.75 | +$4,086,077.75 | 1,091,309 | Indirect | |
| Mar 26, 2025 | Common Stock | PPurchaseAcquired | +58,691 | $43.01 | +$2,524,299.91 | 1,150,000 | Indirect | |
| Mar 27, 2025 | Common Stock | PPurchaseAcquired | +50,000 | $43.55 | +$2,177,500 | 1,200,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.